Testoderm Tts is a drug owned by Alza Corp. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 10, 2019. Details of Testoderm Tts's patents and their expiration are given in the table below.
Get the complete list right in your inbox!
Drug Patent Number
Drug Patent Title
Drug Patent Expiry
Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet,
capsules, liquids etc).
Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.
Get the exclusive patent insights now. Don't be the last to know.
US patents provide insights into the exclusivity only within the United States, but Testoderm Tts is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Testoderm Tts's family patents as well as insights into ongoing legal events on those patents.
Testoderm Tts's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Generic Launch
Generic Release Date:
Testoderm Tts's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 10, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Testoderm Tts Generic API suppliers:
Testosterone is the generic name for the brand Testoderm Tts.
15 different companies have already filed for the generic of Testoderm Tts, with Actavis Labs Ut Inc having the maximum number of approved applications.
Check out the entire list of companies who have already received approval for Testoderm Tts's generic
Alternative Brands for Testoderm Tts
Testoderm Tts which is used for transdermal administration of a drug through non-scrotal skin., has several other brand drugs using the same active ingredient (Testosterone).
Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Testoderm Tts is a drug owned by Alza Corp. It is used for transdermal administration of a drug through non-scrotal skin. Testoderm Tts uses Testosterone as an active ingredient. Testoderm Tts was launched by Alza in 1997.
Approval Date:
Testoderm Tts was approved by FDA for market use on 18 December, 1997.
